Trials / Completed
CompletedNCT05511649
New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
The Prognostic Impacts and Clinical Utility of the Characteristics of New-onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 832 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the prognostic impacts of the atrial fibrillation burden (AFb) in acute myocardial infarction (AMI) patients who developed paroxysmal new-onset atrial fibrillation (NOAF) during the index AMI hospitalization.
Detailed description
In the present study, investigators retrospectively reviewed the medical records of all acute MI patients who were admitted to the coronary artery unit (CCU) of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University between January 2014 and January 2022. All patients will routinely receive continuous electronic monitoring (CEM) throughout their hospital stay to detect cardiac arrhythmias including the AF events. Of these, patients with AMI without a history of AF who developed a first documented AF episode will be considered for inclusion. The AFb is measured as a percentage (%) by dividing the total AF duration by the total CEM duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | continuous electronic monitor | All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2023-07-27
- Completion
- 2023-09-23
- First posted
- 2022-08-23
- Last updated
- 2026-03-19
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05511649. Inclusion in this directory is not an endorsement.